ClinicalTrials.gov
public full text
Public Domain
Anlotinib Treatment in Steroid Depenent/Refractory cGVHD
This is a single center, single arm, prospective, phase II clinical study. The main purpose of this study is to evaluate the efficacy and safety of anlotinib in the treatment of steroid dependent/refractory chronic graft-versus-host disease (cGVHD) after allogeneic peripheral blood stem cell transplantation (allo HSCT).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention#1101964
- Phase II Study of Tocilizumab for Patients With Glucocorticoid-refractory Acute GVHD After Allogeneic Hematopoetic Stem Cell Transplant (HSCT)#1047956
- Papel da anexina A1 na regulação da resposta inflamatória associada à doença do enxerto - versus - hospedeiro#928240
- CK0802 for Treatment of Steroid Refractory Graft vs. Host Disease (GVHD)#855928
- MTX and Steroid for III-IV aGVHD Treatment#1140397
Record · ID 888333
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive